Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
Inova Health System · Sorbonne Université · +40 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,203
total citations
- FWCI
- 99.50
- Percentile
- 100%
- References
- 27
Citations per year
Authors
388- ZMZobair M. Younossi
Inova Health System
- VRVlad Ratziu
Sorbonne Université, Assistance Publique – Hôpitaux de Paris, Fondation pour l’innovation en Cadiométabolisme et Nutrition
- RLRohit Loomba
University of California San Diego
- MEMary E. Rinella
Northwestern University
- QMQuentin M. Anstee
Newcastle upon Tyne Hospitals NHS Foundation Trust, NIHR Newcastle Biomedical Research Centre, Newcastle University
Topics & keywords
Topics
Keywords
- Obeticholic acid
- Interim analysis
- Medicine
- Placebo
- Steatohepatitis
- Interim
- Internal medicine
- Fatty liver
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.
Funding
- ALAbbott Laboratories
- BSBristol-Myers Squibb
- ELEli Lilly and Company
- PPfizer
- AAstraZeneca
- GGlaxoSmithKline
- SSanofi
- GSGilead Sciences
- APAlexion Pharmaceuticals
- CCelgene
- MMedpace
- APArrowhead Pharmaceuticals
- IPIntercept Pharmaceuticals
- NBNGM Biopharmaceuticals
- CBCoherus Biosciences
- NINational Institute for Health and Care Research
- CLChildren's Liver Disease Foundation
- NUNewcastle University
- NNNovo Nordisk
- SServier
- GGenentech
- AAllergan
- NPNovartis Pharma
- BBBirmingham Biomedical Research Centre